Under pressure from generic competition and the looming expiration of patents, Sanofi-Aventis is giving another boost to its pipeline. The French drugmaker said Thursday that it was buying eye ...

When Sanofi-Aventis (SNY) began its attempted takeover of Genzyme (GENZ), everyone thought the company was relatively defenseless against a hostile takeover: It dropped its "poison-pill ...

French drugmaker Sanofi-Aventis SA on Friday shortened its name to Sanofi, the Associated Press reports. Sanofi is one of the world's biggest drugmakers by revenue. It was formed in 2004 in a ...

Drug maker Sanofi-Synthelabo ended weeks of speculation about a friendly merger with Aventis by launching a hostile $60.2-billion takeover bid Monday for its larger rival. Outlining the offer that ...

Sanofi-Aventis shares rose on the announcement, and in mid-afternoon trading Paris time were up 3.5 percent at euro51.56. In U.S. premarket trading, Genzyme stock rose $1.22 to $75.52.

French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the ...

Sanofi-Aventis SA agreed to buy Genzyme Corp., ending a nine-month pursuit of the U.S. biotechnology company with a sweetened offer of at least $20.1 billion that gives France’s biggest ...

Chris Viehbacher, the new CEO of Sanofi-Aventis, poured cold water today on the prospect of Sanofi's doing a deal near the size of Pfizer-Wyeth to plug the big sales gap that will be left for ...

Pharmaceuticals-maker Sanofi-Synthelabo formally announced plans Monday to create the world’s third-largest pharmaceutical company after making a new, “friendly” bid for the Franco-German ...

MannKind Corp.MNKD-1.05%decrease; red down pointing triangle on Tuesday announced the termination of its licensing pact with Sanofi-Aventis in the U.S. for the development and sale of its inhaled ...